

Discussion and Comments Understanding the Microbiome in Women's Health

Cynthia Belew, CNM, WHNP-C

Associate Clinical Professor

University of California San Francisco

cynthia.belew@ucsf.edu



Suggested Clinical Practice

- Be educated about and have index of suspicion for gluten sensitivity disorders
- Be alert for extra-intestinal manifestations of celiac and non-celiac sensitivity

Suggested Clinical Practice

Dietary Fiber

Abundance

Variety

Suggested Clinical Practice

Fermented Foods

- Variety
- Small amounts adequate
- Live cultures
- Weight management, insulin sensitivity, anxiety

Suggested Clinical Practice

Prebiotic Supplements

- Consider for immune, metabolic disorders, weight management, anxiety/stress
- START WITH LOW DOSE and increase gradually
- Theoretical concerns of decreasing diversity – context of dietary counseling re fiber
- Play with genome sequencing of your MB

Suggested Clinical Practice

- Use probiotics where there is abundant evidence on benefits
 - Utilize guidelines to select probiotic strains for specific indications
- View inflammatory disorders as signs of gut dysbiosis, consider prebiotics, probiotics, fermented foods, dietary fiber
 - Anxiety, depression, Obesity, diabetes

Suggested Clinical Practice

- Carefully consider evidence and clinical indications for each antibiotic prescription
 - Decrease presumptive Rx of UTI
 - Avoid unnecessary use of abx for URI
 - Consider learning about the evidence-based use of herbal medicine for URI management
- Give probiotics with antibiotics to:
 - Decrease risk AAD and *C. difficile*
 - Decrease inflammation, heal gut mucosa

Suggested Clinical Practice

- Narrowest spectrum and shortest duration
- Avoid Rx of Asymptomatic BV in Pregnancy
- Use clinical triggers to minimize duration of exposure to IAP
 - Exposure > 24hr linked w atopic disease
- Investigate risk scoring strategies for antibiotic prophylaxis at Cesarean, MROP

Suggested Clinical Practice

- Decrease GBS Colonization
 - Support preg MB and immune function
 - Fermented foods, fiber
 - Consider probiotic in early 3rd trimester
 - Esp if high risk for GBS
 - *L. rhamnosus* GR-1 and *L. reuteri* RC-14
- Develop decision aids for IAP
- Use probiotics to treat/augment treatment for Bacterial Vaginosis

ESTROGEN METABOLISM

L rhamnosus GR-1 and L reuteri RC-14 – not vaginal

- Anti-inflammatory effects in IBD patients (Lorea Baroja)
- Improves diarrhea in persons with HIV/AIDS (Anukam 2008)
- Decreases mercury and ___ uptake in pregnancy

Prevention/treatment of mastitis

- Prevention: Probiotic 30 weeks GA until birth
 - Mastitis in first 3 months postpartum decreased:
 - 25% probiotic, 47% placebo $P=0.001$
 - Infections less severe w probiotic
 - lower colony counts and pain scores
 - *L salivarius* PS2, available commercially
- Treatment:
 - Cure higher in probiotic than antibiotic group
 - by colony counts ($p<0.01$)
 - By pain symptoms
 - Recurrence rate higher in abx group ($p<0.001$)
 - *L fermentum* CECT5716 or *L salivarius* CECT5713



Fernández et al (2016). Clinical infect dis, 62(5), 568-573; Arroyo et al(2010). Clin infect ds, 50(12), 1551-1558.

Vaginal chlorhexidine during labor for GBS prevention

- Four studies, 1125 infants, term and preterm
- No difference in early-onset GBS disease
- May be a reduction in neonatal colonization with GBS
- Low quality evidence
- Wipes out normal flora

Maternal Outcomes

Gestational Diabetes

Preeclampsia

Reduced risk mastitis

Reduced postpartum central adiposity

Outcomes in the offspring

Reduced risk of eczema

Restoration of MB in Cesarean-born infants

PROBIOTICS IN PREGNANCY REVIEW OF EVIDENCE

Probiotics in pregnancy and maternal outcomes: a systematic review

- Six RCT's, one prospective cohort study
- Significant reductions in:
 - Maternal fasting glucose
 - Incidence of GDM
 - Incidence of preeclampsia
 - Severe preeclampsia OR 0.61, 95% CI 0.43-0.89
 - Levels of C-reactive protein
 - Central adiposity at six months postpartum (OR 0.30)

GDM and probiotics:

Decreased GDM incidence three-fold (Luoto)

- 13% w probiotic 36% with no intervention $p=0.003$
- Also reduced fetal macrosomia
- *L rhamnosus GG* and *B lactis Bb12*
- Single products available, Nestle just filed for a patent for this combo

• In women with GDM:

- Improved FPG, serum insulin, insulin sensitivity in women with GDM, all statistically significant (Karamali; Dolatkhan)
- Six weeks of *L acidophilus*, *L casei*, *B Bifidum* vs placebo
- Modulate inflammatory markers in GDM (VSL3)
- Decrease wt gain and FBG

Karamali et al (2016). *Diabetes & metabolism*, 42(4), 234-241. Jafarnejad et al(2016). *Jo Nutri Metabolism*, 2016, 5190846-5190846; Luoto et al (2010). *British Jo Nutrition*, 103(12), 1792-1799; Dolatkhan et al (2015). *Jo Health, Pop Nutr*, 33, 25-25

Probiotics: Reduced postpartum central adiposity and blood glucose

- Dietary counseling plus probiotic or placebo, first trimester
 - Central adiposity: risk lower at 6 mo postpartum
 - OR 0.03; 95% CI 0.11-0.85
 - Glucose regulation better during pregnancy and until 12 months postpartum
 - P=0.013
 - *L rhamnosus GG* ATCC53103 and *B lactis*

Ilmonen et al(2011). Clinical nutri, 30(2), 156-164;
Laitinen e al (2009). British Jo Nutr, 101(11), 1679-1687.

Suggested Clinical Practice

- Consider use of prebiotics, fermented foods, dietary fiber and probiotics as a supportive measure in prevention and treatment of diabetes

Eczema risk in offspring

- Prenatal probiotic use decreased incidence eczema
- World Allergy Association: approved for prevention of eczema if there is a family history of eczema
- Less evidence for asthma, food allergy, allergic rhinitis
- Effective species:
 - L rhamnosus GG 53103
 - Bifidobacteria lactis Bb-12

West, Jenmalm et al 2016; Kuitunen et al 2009, Pelucchi et al 2012,, Panduru et al 2015; Kalliomäki et al (2003) The Lancet, 361(9372), 1869-1871

Suggested Clinical Practice

- Consider prenatal use of probiotics for decreased risk of eczema in the offspring, in women with a family history of allergic disease